RBC Capital Maintains a Buy on Nuvation Bio (NUVB) With a $6 PT

Nuvation Bio Inc. (NYSE:NUVB) is one of the best biotech penny stocks to buy right now. In a report released on July 7, Leonid Timashev from RBC Capital maintained a Buy rating on Nuvation Bio Inc. (NYSE:NUVB), setting a price target of $6.00.

Is Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

A close-up of researchers, carefully studying a biopharmaceutical compound in a laboratory.

On June 11, Nuvation Bio Inc. (NYSE:NUVB) announced the US Food and Drug Administration’s (FDA) approval of IBTROZI (taletrectinib) to treat adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

IBTROZI is a highly selective, next-generation oral ROS1 tyrosine kinase inhibitor (TKI) that addresses some of the outstanding challenges associated with the treatment of ROS1+ NSCLC.

The product is generally well tolerated and exhibits a high response rate with durable benefit and intracranial activity, offering a new treatment option for advanced ROS1+ NSCLC.

Nuvation Bio (NYSE:NUVB) is a biopharmaceutical company that develops therapeutic and differentiated candidates to tackle the gaps in oncology.

It is advancing several clinical-stage candidates, including a bromodomain and extra-terminal (BET) inhibitor, a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, and a drug-drug conjugate (DDC).

While we acknowledge the potential of NUVB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than NUVB and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.